Millennium Management

Millennium Management LLC is a privately owned investment management firm founded in 1989 and headquartered in New York City, with additional offices in several international locations including London, Old Greenwich, Singapore, Hong Kong, Geneva, and Minatu-ku. The firm specializes in multi-strategy hedge fund management, employing a diverse range of investment strategies that encompass relative value, fundamental equity, statistical arbitrage, merger arbitrage, and event-driven approaches. Millennium invests across various asset classes, including equities, fixed income, foreign exchange, commodities, and derivatives, utilizing sophisticated resources and technology to enhance its investment processes. By focusing on pooled investment vehicles, Millennium aims to deliver compelling returns through a global investment approach that spans multiple industry sectors and geographies.

Hunter Merghart

COO, Digital Assets

16 past transactions

Caris Life Sciences

Private Equity Round in 2025
Caris Life Sciences, Inc. is a biotechnology company specializing in molecular profiling and advanced diagnostic technologies aimed at improving cancer patient outcomes. Founded in 1987 and headquartered in Irving, Texas, with additional offices in Phoenix and Basel, the company develops solutions that leverage artificial intelligence and machine learning to analyze the molecular complexity of diseases. Caris offers a range of services, including anatomic pathology, drug development, and molecular analyses of patient samples, which include genomic, transcriptomic, and proteomic profiling. Their Comprehensive Oncology Data Explorer serves as a clinico-genomic data platform. By providing insights into DNA, RNA, and protein profiles, Caris enables healthcare professionals to make more precise and personalized treatment decisions for oncology and other complex diseases. The company operates through distributors across the United States, Europe, Australia, and globally, and has established strategic collaborations to enhance its offerings.

Cardurion Pharmaceuticals

Series B in 2024
Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Carmot Therapeutics

Series E in 2023
Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, it focuses on discovering and developing innovative therapies for patients with metabolic diseases, including obesity and diabetes. Utilizing its proprietary Chemotype Evolution technology, Carmot Therapeutics aims to address the underlying causes of these conditions and accelerate the discovery of effective treatments. The company’s portfolio includes several clinical-stage drug candidates, such as CT-388 and CT-996, which are designed as GLP-1 receptor agonists for the treatment of obesity and type 2 diabetes, and CT-868, intended for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to create life-changing therapeutics that improve the health outcomes of individuals affected by metabolic diseases.

One97 Communications

Post in 2022
One97 Communications Limited is a mobile payments services company based in Noida, India, founded in 2000. It operates under the Paytm brand, offering a comprehensive range of mobile content and commerce services. The company provides digital goods and services, including top-ups, ticket bookings, hotel reservations, music, videos, games, and other mobile content. Additionally, One97 Communications is a leading provider of payment solutions for e-commerce merchants, utilizing its RBI-approved semi-closed wallet. With a workforce of over 4,500 employees, the company has a wide geographical footprint, with regional offices in major Indian cities such as Mumbai, Bengaluru, Pune, Chennai, and Kolkata, as well as a global presence in Africa, Europe, the Middle East, and Southeast Asia.

Metagenomi

Series B in 2022
Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Himachal Futuristic Communications Limited

Post in 2021
HFCL Limited is a company that focuses on the manufacturing of telecommunication equipment. It provides a range of products and services aimed at enhancing communication infrastructure. HFCL plays a vital role in supporting the growing demand for advanced telecommunications solutions, contributing to the development of both domestic and international communication networks. The company is involved in various sectors, including broadband, mobile, and data communication, thereby facilitating connectivity and technological advancement. Through its innovative offerings, HFCL aims to address the evolving needs of the telecommunications industry.

Palladyne AI

Post in 2021
Palladyne AI is a software company specializing in advanced robotic technology that enhances the intelligence and efficiency of robotic systems. By leveraging artificial intelligence and machine learning, Palladyne AI's platform enables robots to observe, learn, reason, and act in ways that closely resemble human intelligence. This innovative software empowers robots to autonomously adapt to dynamic environments, allowing them to perceive and respond to changes in real-time. The applications of Palladyne AI's technology span various industries, including automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics, and warehousing, positioning the company as a key player in the evolution of robotics.

Market Kurly

Series F in 2021
Market Kurly is an online grocery service based in Seoul, South Korea, that specializes in the delivery of fresh and premium food products. Founded in 2014, the platform allows users to order a wide range of items, including vegetables, fruits, meats, dairy, baked goods, and processed foods, all sourced directly from producers. Market Kurly focuses on providing high-quality ingredients and offers next-day delivery, ensuring that customers receive their orders promptly. The service also includes non-perishable items, enabling shoppers to conveniently access a variety of groceries. Through its innovative logistics and delivery system, Market Kurly aims to enhance the grocery shopping experience by transforming the way food is produced and distributed.

Payoneer

Post in 2021
Payoneer Inc., established in 2005, operates a global cross-border payments platform. It facilitates international transactions for businesses, enabling them to receive local bank transfers and funds from various marketplaces and partners directly to their Payoneer account or bank account. The company offers services such as the Global Payment Service, which provides access to multiple receiving accounts in the U.S., EU, and Japan, and mass payout services for Indian companies. Payoneer caters primarily to freelancers, e-commerce, and online advertising industries, and has strategic partnerships with several companies. It is headquartered in New York, New York.

Quanta

Series D in 2021
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Caris Life Sciences

Private Equity Round in 2021
Caris Life Sciences, Inc. is a biotechnology company specializing in molecular profiling and advanced diagnostic technologies aimed at improving cancer patient outcomes. Founded in 1987 and headquartered in Irving, Texas, with additional offices in Phoenix and Basel, the company develops solutions that leverage artificial intelligence and machine learning to analyze the molecular complexity of diseases. Caris offers a range of services, including anatomic pathology, drug development, and molecular analyses of patient samples, which include genomic, transcriptomic, and proteomic profiling. Their Comprehensive Oncology Data Explorer serves as a clinico-genomic data platform. By providing insights into DNA, RNA, and protein profiles, Caris enables healthcare professionals to make more precise and personalized treatment decisions for oncology and other complex diseases. The company operates through distributors across the United States, Europe, Australia, and globally, and has established strategic collaborations to enhance its offerings.

Deep Instinct

Series D in 2021
Deep Instinct Ltd. is a cybersecurity company founded in 2014 and headquartered in Tel Aviv, Israel, with an additional office in New York, New York. The company specializes in developing advanced cybersecurity solutions that utilize artificial intelligence and deep learning technology to detect and prevent zero-day threats and advanced persistent threat attacks in real-time. Its platform offers comprehensive protection across various mobile devices, endpoints, and operating systems, regardless of whether they are connected to a network or the Internet. By leveraging deep learning's predictive capabilities, Deep Instinct enables enterprises to safeguard their infrastructures against unknown and evasive cyber threats, identifying and blocking attacks before they can cause harm.

Starling Bank

Series D in 2021
Starling Bank Limited is a digital-only bank based in London, United Kingdom, founded in 2014. It specializes in providing personal, joint, and business banking services through a mobile platform. The bank offers a range of financial services, including digital banking, real-time spending intelligence, and personalized banking options. Customers can manage their accounts entirely online, benefiting from features such as same-day payments and comprehensive financial management tools. Starling Bank aims to facilitate a seamless, paperless banking experience for its users.

WeDoctor

Series F in 2021
WeDoctor is a prominent medical health technology platform founded in 2010 by Liao Jieyuan and his team. The company aims to enhance access to healthcare by leveraging technology to provide a comprehensive range of services. Its mobile application allows users to connect with hospitals and doctors, schedule appointments, and access medical advice and ratings for healthcare providers. By integrating both online and offline medical services, WeDoctor aspires to serve as a health management organization, facilitating improved healthcare experiences for millions of families. The platform emphasizes a user-friendly approach to healthcare, making essential medical services readily available and efficient.

SomaLogic

Series A in 2020
SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Caris Life Sciences

Private Equity Round in 2020
Caris Life Sciences, Inc. is a biotechnology company specializing in molecular profiling and advanced diagnostic technologies aimed at improving cancer patient outcomes. Founded in 1987 and headquartered in Irving, Texas, with additional offices in Phoenix and Basel, the company develops solutions that leverage artificial intelligence and machine learning to analyze the molecular complexity of diseases. Caris offers a range of services, including anatomic pathology, drug development, and molecular analyses of patient samples, which include genomic, transcriptomic, and proteomic profiling. Their Comprehensive Oncology Data Explorer serves as a clinico-genomic data platform. By providing insights into DNA, RNA, and protein profiles, Caris enables healthcare professionals to make more precise and personalized treatment decisions for oncology and other complex diseases. The company operates through distributors across the United States, Europe, Australia, and globally, and has established strategic collaborations to enhance its offerings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.